Compare Adaptive Biotechnologies Corp (ADPT) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Sprott Uranium Miners ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.98 (market cap $4.04B), while Sprott Uranium Miners ETF trades at $55.5. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | URNM | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $25.45 | $83.99 |
52-Week Low | $12.30 | $44.14 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
URNM trades at $55.97, up 2.51% today, with a bullish technical signal driven by moving averages. The ETF focuses on uranium miners, benefiting from nuclear energy's resurgence. Recent news highlights significant government funding and AI-driven power demand as catalysts. Key support is at $55, with resistance at $56.
The outlook is positive due to structural uranium supply deficits and growing nuclear adoption, but risks include volatility from spot price swings and concentrated miner exposure. Analyst sentiment is mixed, with some favoring pure-miner exposure while others caution on valuation gaps versus underlying uranium prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
